Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Active, not recruiting · NCT04126070 · Registry updated 2026-08-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors | prostate adenocarcinoma | Active, not recruiting | Phase 2 | 2026-08-12 | NCT04126070 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Bristol-Myers Squibb | 422 |
| Xiao X. Wei, MD | 1 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |
| Dana Farber Cancer Institute | Boston | United States | 133 |
| H. Lee Moffitt Cancer Center | Tampa | United States | 13 |
| The Johns Hopkins University School of Medicine | Baltimore | United States | 2 |
| University of California, San Diego | La Jolla | United States | 38 |
| University of Wisconsin | Madison | United States | 10 |